Edition:
United Kingdom

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

4.78USD
13 Dec 2017
Change (% chg)

$0.03 (+0.53%)
Prev Close
$4.75
Open
$4.70
Day's High
$4.80
Day's Low
$4.70
Volume
7,702
Avg. Vol
21,614
52-wk High
$7.20
52-wk Low
$3.55

Latest Key Developments (Source: Significant Developments)

Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Axsome Therapeutics Inc ::SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING.  Full Article

Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE.AXSOME THERAPEUTICS INC - ‍PHASE 3 TRIAL ANTICIPATED IN 2018​.AXSOME THERAPEUTICS INC - AXS-07 HAS ‍POTENTIAL FOR "SUPERIOR" EFFICACY AS COMPARED TO CURRENT TREATMENTS​.AXSOME THERAPEUTICS INC - ‍U.S. FDA PRE-INVESTIGATIONAL NEW DRUG APPLICATION​ MEETING WRITTEN GUIDANCE RECEIVED.  Full Article

Axsome Therapeutics reports Q3 loss per share $0.27
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Axsome Therapeutics Inc :Axsome Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.27.Axsome Therapeutics Inc - ‍Believes its cash as of Sept. 30, 2017 will be sufficient to fund anticipated operations into Q1 of 2019​.  Full Article

Axsome Therapeutics reports Q2 loss per share $0.36
Tuesday, 9 Aug 2016 

Axsome Therapeutics Inc : Axsome Therapeutics reports second quarter 2016 financial results . Q2 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.36 .Currently anticipates that its cash will be sufficient to fund its anticipated operations into q3 of 2017.  Full Article

Axsome Therapeutics previously reported net loss for year ended Dec. 31 understated
Tuesday, 12 Jul 2016 

Axsome Therapeutics : Non-Cash $1.65 million premium associated with convertible notes, should have been recorded directly to additional paid in capital . Correction of reporting error to have no impact on cash, total assets, stockholders' equity, loss from operations, cash flows . Due to reporting error, previously reported interest, other income (expense) net loss for year ended Dec 31, 2015 were understated .Will file amendment to annual report on form 10-k for year ended dec 31, 2015 restating financial statements for year ended dec 31, 2015.  Full Article

Axsome Therapeutics Q1 loss per share $0.31
Wednesday, 11 May 2016 

Axsome Therapeutics Inc : Its cash will be sufficient to fund its anticipated operations into q3 of 2017 . Axsome therapeutics reports first quarter 2016 financial results .Q1 loss per share $0.31.  Full Article

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage: